Non-Carbohydrate Inhibitors of Sialic Acid-binding Immunomodulatory-type Lectin-7 (Siglec-7) Discovered from Genetically Encoded Bicyclic Peptide Libraries
Authors:
- Danial YazdanDYDanial Yazdan
- A. Michael DowneyADA. Michael Downey
- Ana GimenoAGAna Gimeno
- Caishun LiCLCaishun Li
- Edward N. SchmidtESEdward N. Schmidt
- Jeffrey Y. K. WongJWJeffrey Y. K. Wong
- Caleb LooCLCaleb Loo
- Jaesoo JungJJJaesoo Jung
- Ryan QiuRQRyan Qiu
- Ewa LisELEwa Lis
- Lily LindmeierLLLily Lindmeier
- June Ereño-OrbeaJune Ereño-Orbea
Preprint
Abstract
Glycan-binding proteins (GBP) are among the most difficult to drug targets. This deficiency delays clinical progress for therapeutically important GBPs. We employed bicyclic genetically encoded libraries (BiGELs), produced by chemical modification of phage-displayed libraries of peptides with two-fold symmetric linchpins, to discover inhibitors of therapeutically relevant Siglec-7:GD3 interactions. Next-generation sequencing (NGS) analysis of panning of BiGEL against Siglec-7 yielded 815 candidates from which 23 hits yielded K D = 1−100 µM as determined by surface plasmon resonance (SPR). Competitive enzyme-linked immunosorbent assays (ELISA) identified a subset of leads that disrupted the Siglec-7:GD3 interaction with IC 50 = 3−300 µM. Machine learning models trained on NGS datasets identified additional inhibitors with equivalent potency. Alanine scans of 8c (SWCRPATVNC, IC 50 = 3.8 µM) and 12c (SFCHYPTHVC, IC 50 = 11 µM), identified key residues as crucial for activity. Ring reshaping studies of compound 8c highlighted the critical role of bicyclic topology produced by analogue 46e (SAAAAAWCRPATVNC, IC 50 = 9.5 µM). Multivalent display of the lead bicycles alongside ∼100 glycans in Liquid glycan Array (LiGA), made it possible to compare the binding of bicycles and glycans to Siglec-7 expressed on CHO, Jurkat, and Raji cells. LiGA assays confirmed binding of the bicycles to Siglec-7 but revealed considerable non-specific interactions with receptor-negative cells. Saturation transfer difference nuclear magnetic resonance (STD-NMR) revealed 46e binds to Siglec-7 at a site distinct from the V-Ig domain, suggesting it might inhibit binding of glycans to the glycan-binding site of Siglec-7 via an allosteric site. Together these results demonstrate that BiGEL enables the discovery of bicyclic peptides for undruggable Siglec targets but highlights future challenges in molecular discoveries that aim to identify small, non-carbohydrate inhibitors of GBPs.Keywords
Funding Information
- Natural Sciences and Engineering Research Council (RGPIN-2022 04484)
- Natural Sciences and Engineering Research Council Accelerator Supplement
- Canada Foundation for Innovation new leader opportunity
This publication has 53 references indexed in Scilit:
- The glycoimmune checkpoint receptor Siglec-7 interacts with T-cell ligands and regulates T-cell activationJournal of Biological Chemistry, 2023
- Discovery of Selective and Orally Available Galectin-1 InhibitorsJournal of Medicinal Chemistry, 2023
- Selective oligosaccharide recognition with phenylboronic acid through Cu(I)-catalysed click imprinted surfacesMaterials Today Chemistry, 2022
- Glycosylation in cancer: Selected roles in tumour progression, immune modulation and metastasisCellular Immunology, 2018
- Rapid Discovery of Potent and Selective Glycosidase-Inhibiting De Novo PeptidesCell Chemical Biology, 2017
- Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based ApproachesTrends in Pharmacological Sciences, 2015
- Synthesis and biological evaluation of 9-N-oxamyl sialosides as Siglec-7 ligandsBioorganic & Medicinal Chemistry, 2015
- Peptide therapeutics: current status and future directionsDrug Discovery Today, 2015
- Next-Generation Sequencing of Phage-Displayed Peptide Libraries2014
- A monosaccharide-modified peptide phage library for screening of ligands to carbohydrate-binding proteinsBioorganic & Medicinal Chemistry Letters, 2013